Block a user
320cbe4ef2
Deep dive: Pinealon (PEPTIDES.md Section 4.3, Tier 4 — Avoid) — replaces previously lumped mention within Khavinson section with full ~219-line analysis. Discovery: Khavinson group St Petersburg, Glu-Asp-Arg tripeptide as cytogen subset. Proposed Khavinson mechanism (site-directed DNA binding to promoter regions, cell-penetration, transcription factor mimicry, organ-specific gene regulation). Information-theoretic objection as central critique: 3-mer = ~13 bits sequence info vs ~31.5 bits needed for unique site in 3 Gb genome — gap is intrinsic. Three additional convergent biophysics objections: serum peptidase kinetics, absent CPP structural motifs, no ITC/SPR confirmation. Animal evidence covered (Khavinson rodent studies on cognition/ischemia/aging). Human evidence gap (only small unblinded Russian trials). Twitter/social media promotion concern noted honestly. Sourcing concerns (Russian vendors, unverifiable purity). Safety profile (limited Khavinson tox only). Genotype interactions (APOE ε4, DIO2 het, CLOCK CC). Evidence summary table 8 claims. 14 references. Framework alignment: Tier 4 on mechanism implausibility AS CLAIMED + evidence quality grounds. Not claiming biologically inert — door left open for downstream effect via free amino acids or NO-substrate Arg. §4.2 Khavinson reframed as broader methodological critique. GLP-1 cross-ref bumped 4.3 → 4.4. File 734 → 963 lines.
c7e0428468
Create PEPTIDES.md — new sibling document to SUPPLEMENTS.md covering therapeutic peptides through the bioenergetic longevity framework lens. 734 lines, 22 peptide entries plus framework intro. Tier structure: Tier 1 Strongly Aligned (MOTS-c, SS-31/Elamipretide, Humanin, Thymosin α-1), Tier 2 Aligned Context-Dependent (BPC-157, TB-500, GHK-Cu, PDA, LL-37, Selank, Semax, DSIP, Thymalin), Tier 3 Mixed/Complicated (Tesamorelin, Sermorelin, CJC-1295 with/without DAC, Ipamorelin, Hexarelin, MK-677, Cerebrolysin, PT-141, Kisspeptin-10, Melanotan I), Tier 4 Avoid (Melanotan II, Khavinson school bioregulators incl Epitalon, GLP-1 cross-ref to SUPPLEMENTS 4.7). BPC-157 full deep dive (~218 lines): Sikiric Zagreb origin, GEPPPGKPADDAGLV pentadecapeptide, oral vs SC bioavailability controversy, 6-mechanism breakdown with ASCII diagram (NO/eNOS, VEGF, GHR upregulation, FAK-paxillin, brain-gut, monoaminergic), 15+ rodent indications, explicit human-RCT-gap flag, VEGF cancer concern analysis, dosing, genotype interactions, stack interactions, sourcing concerns, 18 key references, evidence summary table. Framework intro covers bioenergetic application to peptides, route/bioavailability primer, research-chemical sourcing problem, cancer concerns for growth-promoting peptides. Framework consistency calls: GH-axis peptides Tier 3 (chronic IGF-1 → mTOR override), MK-677 flagged near Tier 4 (24h sustained vs pulsatile), CJC-1295 with-DAC vs without-DAC split, Melanotan I/II split, Khavinson school Tier 4 with honest evidence framing. Stubs for all non-BPC-157 entries ready for future deep dives.
5665d74e32
Deep dive: Rapamycin (Section 4.4, Tier 4 — Avoid) — replaces 5-line stub with full ~420-line analysis. Discovery from Streptomyces hygroscopicus on Rapa Nui (1972), CYP3A4 metabolism with CYP3A4*22 pharmacogenomic concern. FKBP12-FRB binding mechanism with full mTORC1 vs mTORC2 architecture diagram. Mouse evidence: Harrison 2009 ITP (9-14% lifespan extension), Miller 2011/2014 dose-dependent, Wilkinson 2012 female bias, Bitto 2016 brief treatment sufficient. Mouse-to-human translation problems: cancer-dominated mouse mortality, species-specific mTOR signaling differences, lab mouse environmental artifacts. Human evidence: PEARL trial (2023) NEGATIVE on primary endpoints, Mannick 2014/2018 RAD001 vaccine response (specific not generalizable), transplant cohort no anti-aging signal. Side effect profile (table): hyperlipidemia 50-80%, glucose intolerance, mouth ulcers 30-50%, edema, wound healing impairment, immunosuppression, pneumonitis, proteinuria. Framework's six mechanistic objections: anti-anabolic (Drummond 2009, Dickinson 2011), anti-glucose-oxidation (Lamming 2012, TCF7L2 TT amplification), anti-thyroid CR-mimetic profile (DIO2 het), anti-mitochondrial-biogenesis (Cunningham 2007, UA/cordyceps preferred), immunosuppression, wound healing/fertility. Blagosklonny hyperfunction theory critique. Genotype interaction table covering CYP3A4*22, TCF7L2, APOE ε4, DIO2, TNF-α, methylation hets, UCP2/J1c, FOXO3, COL1A1, 9p21, TERT. Low-dose intermittent defense and its limits. Stack interactions: metformin double-negative, statins additive, urolithin A preferred alternative, exercise adaptation abolished. Specific clinical scenarios where rapamycin IS appropriate (TSC, LAM, transplant, RCC, drug-eluting stents, HGPS). Evidence summary table 14 claims. 16 references. Harm reduction protocol if used against recommendation.
6d88496404
Restore lost Tier 4 + Appendix A content (1231 sanitized lines). The original commit pushing SUPPLEMENTS.md to this repo was already missing this content (lost in upstream commit 1afbfe5 which dropped the file from 20,238 → 19,413 lines while adding the Alpha-Lipoic Acid section — the Tier 4 header was preserved but everything below it was truncated). Restored from upstream peak commit 264505c with personal references sanitized: Section 4.1 Statins (stub), Section 4.2 Metformin (full deep dive: Complex I/ND3 inhibition, Konopka 2019 exercise blunting, Aroda 2016 B12 depletion, mGPD inhibition, GI serotonin, TSH suppression, TAME framework interpretation, AMPK alternatives table), Section 4.3 High-Dose Antioxidants (stub), Section 4.4 Rapamycin (stub), Section 4.5 Fluoride (stub), Section 4.6 Iron — Dietary Yes Supplemental No (~254 lines), Section 4.7 GLP-1 Receptor Agonists (~420 lines: STEP/SELECT/SUSTAIN/FLOW trials, lean mass loss, MTC black box, GI pathology, metabolic suppression, TCF7L2 TT pharmacogenomic counterargument), Appendix A Excipients & Additives. Sanitized: 'this user' → 'someone with this profile', 'BMI 19.4 / 58 kg' → 'lean adult / low BMI', 'the user's X genotype' → 'X genotype (in carriers)', 36-year-old male → adult. File now 20,983 lines.
efd4983fed
Correct framework framing of mannoheptulose in avocado section. Original framing pitched mannoheptulose as a longevity-positive bonus via 'CR mimetic' effect — this is mechanistically inconsistent with the framework's actual stance. Hexokinase inhibition suppresses glucose oxidation (the framework's preferred fuel pathway), forces fat oxidation via Randle cycle, mimics caloric restriction (which the framework views as anti-thyroid, pro-cortisol, metabolic-rate-suppressing). Mannoheptulose mechanistically belongs in the same category as metformin, rapamycin, acarbose, berberine — drugs the framework is skeptical of. The CR longevity benefit (where it exists) more plausibly attributes to PUFA depletion than to glucose restriction. Re-framed as 'framework-cautionary, not framework-positive', noted that dietary dose from ripe avocado (~600mg) is 25-50x below pharmacological threshold (15-30g human equivalent) so practically inert. Flagged as framework-contraindicated: eating unripe avocados for mannoheptulose, mannoheptulose supplements, stacking with other glucose-suppressing strategies. Updated framework alignment summary line accordingly.
787a921511
Add Section 3.5 — Berries: comprehensive deep-dive on botanical diversity, anthocyanins, and framework significance. Botanical taxonomy clarification (true berries vs aggregate fruits vs accessory fruits): only blueberry of the four common 'berries' is botanically a true berry. Strawberry achene story (150-200 achenes per fruit, each a separate dry one-seeded fruit; flesh is enlarged receptacle tissue). Raspberry/blackberry drupelet structure. Three framework consequences of seed architecture: polyphenol distribution (seeds polyphenol-rich), PUFA load from seeds (intact seeds resist digestion but berry seed oil supplements bypass this — framework caution), fibre delivery. Anthocyanin chemistry: 6 dominant anthocyanidins per berry; bioavailability paradox resolved via microbial metabolites (protocatechuic acid etc), local gut effects, tissue accumulation. Documented systemic effects (vascular, anti-inflammatory, cognitive — Krikorian 2010, glucose, microbiome, antiplatelet). Other polyphenols: ellagitannin → urolithin A pathway with converter caveat (~30-40% population), type-A PACs in cranberry (UTI mechanism — P-fimbriae anti-adhesion), pterostilbene, fisetin, quercetin, resveratrol. 17 individual berry profiles (blueberry, bilberry, cranberry, strawberry, red/black raspberry, blackberry, currants, gooseberry, mulberry with DNJ, goji, acai, sea buckthorn with palmitoleic acid, lingonberry, aronia, maqui, camu camu, sour cherry). Glycemic load comparison. Frozen vs fresh (frozen wild blueberries often superior). Pesticide considerations (strawberries #1 EWG Dirty Dozen). Berry seed oil supplements caution. Strongly aligned verdict; recommended pattern. 15 references.
f6ed2d114f
Add Section 1.6 — Avocado (Whole Fruit and Oil) to DIET.md. Comprehensive deep-dive between Olive Oil and Protein Sources. Hass cultivar dominance noted; lipid profile per 100g flesh and per medium fruit (~67% oleic, ~12% LA = 2.6g LA per fruit, ~6% palmitoleic). PUFA reality check vs marketing claims. Avocado oil adulteration crisis (Wang & Reardon 2020 UC Davis: 82% of commercial samples rancid or adulterated with high-oleic sunflower oil); verified-pure brand list (Marianne's, Bella Vado, CalPure, Olivado, Grove, La Tourangelle), failed brands. Smoke point analysis (refined ~270C, virgin ~190C). Unique bioactives: mannoheptulose (hexokinase inhibitor / CR mimetic in unripe fruit), avocatin B (CPT1 inhibitor, AML selective cytotoxicity, in seed), beta-sitosterol (phytosterol with Helgadottir 2020 phytosterol-CHD caveat), persin (pet toxicity). Micronutrient profile: highest fruit potassium 485mg/100g, B5/folate/copper/K1, lutein+zeaxanthin with Unlu 2005 fat-absorption synergy. Antinutrients: clean overall; latex-fruit syndrome cross-reactivity, tyramine for MAOI/migraine, histamine for MCAS. Glucose handling and framework caveat on postprandial pathologisation. Comparison table vs other fat sources. Environmental/ethical (water use, cartel involvement, deforestation). Practical use, frequency 0.5-1/day. Aligned with caveats verdict. 11 references.
eb979a8fa7
Expand Section 7.3 — Tree Nut Butter Comparison: comprehensive lipid and antinutrient deep-dive. Replaces brief stub with structured comparison covering hazelnut, cashew, almond (full per-nut profiles), plus walnut/pecan/pistachio/Brazil. Lipid profile table for all 5 main nut butters with bis-allylic/peroxidation theory (4-HNE, MDA, isoprostanes, cardiolipin damage cycle). Antinutrient mechanism deep-dives: phytate (IP6 chelation chemistry, mineral binding constants, phytate:zinc ratios, mitigation), oxalate (kidney stones + PDH/Complex II inhibition + Oxalobacter formigenes microbiome interaction), lectins (PNA T-antigen binding), tannins, mycotoxin sources (aflatoxin B1 hepatocarcinogenesis, TP53 R249S signature). Hazelnut: oleic dominance, source-dependent aflatoxin (Turkey vs Italy/Oregon). Cashew: high SFA/stearic mitochondrial fusion benefit, oxalate concern. Almond: borderline-to-avoid analysis (24% PUFA, 469mg/100g oxalate, 140:1 phytate:zinc ratio, LDL-trial framing critique). Final ranking table 1-5 with mitigation strategies for sub-optimal choices. 15 references.
181eb79b49
Add supplements deep-dive compendium — 35 Tier 1-3 sections + 7 Tier 4, covering 9 medicinal mushrooms, mitochondrial supplements, methylation support, metal detoxification agents, and more